(NASDAQ: ATAI) Ataibeckley's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Ataibeckley's earnings in 2026 is -$663,398,000.On average, 16 Wall Street analysts forecast ATAI's earnings for 2026 to be -$170,497,987, with the lowest ATAI earnings forecast at -$277,818,572, and the highest ATAI earnings forecast at -$135,301,253. On average, 14 Wall Street analysts forecast ATAI's earnings for 2027 to be -$165,564,553, with the lowest ATAI earnings forecast at -$220,090,038, and the highest ATAI earnings forecast at -$139,167,003.
In 2028, ATAI is forecast to generate -$183,420,637 in earnings, with the lowest earnings forecast at -$277,818,572 and the highest earnings forecast at -$112,106,752.